[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-exacerbations\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-exacerbations":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,57,91,120,147,180,205,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100623465","boosting-referrals-to-asthma-specialists-for-patients-seen-at-the-emergency-room-for-an-asthma-exacerbation-100623465",false,"NCT07396987","Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","Inclusion Criteria:\n\n* Age ≥18 years\n* Asthma diagnosis ≥1 year\n* Seen in ER for asthma exacerbation\n* Persistent asthma on controller therapy\n* ≥1 asthma exacerbation in prior year\n\nWe will allow for current smokers, vapers and cannabis users as long as they have not been diagnosed with COPD and have a smoking history \\\u003C10 pack-years.\n\nWe will allow for COPD as long as they are:\n\n1. never smokers\u002Fvapers\u002Fcannabis users; or\n2. former or current smokers\u002Fvapers\u002Fcannabis users with normal pulmonary function tests (PFT; FEV1\u002FFVC ratio of \\>70%) within 12 months of enrollment and a smoking history \\\u003C10 pack-years; or\n3. current or former smoker\u002Fvapers\u002Fcannabis users with obstruction on PFTs (FEV1\u002FFVC ratio of \\\u003C70%) but who demonstrate BOTH \\>10% acute bronchodilator reversibility AND a normal diffusing capacity both within 12 months of enrollment (stricter criteria than those used in the PREPARE trial (15) and a smoking history \\\u003C10 pack-years.\n\nExclusion Criteria:\n\n* Patients who have seen an asthma specialist (allergist or pulmonologist) for asthma in the past 2 years\n* Diagnosis of other pulmonary diseases (e.g., COPD, interstitial lung disease, etc.)","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is testing a new way to help adults with asthma get follow up care after an emergency room (ER) visit for an asthma attack. Many people who come to the ER for asthma never see an asthma specialist afterward, even though specialists can offer treatments such as advanced inhalers or biologic medicines that may prevent future attacks.\n\nThe study will compare two approaches. One group will receive a telehealth appointment with an asthma specialist that is scheduled for them before they leave the ER. The other group will receive the usual care, which typically includes a standard referral but no scheduled appointment. All participants will be offered a prescription for standard controller medication at discharge.\n\nThe main question the study aims to answer is whether arranging a telehealth visit directly from the ER increases the number of patients who complete a follow up appointment with an asthma specialist within three months. The study will also look at whether this approach improves asthma control, reduces repeat ER visits, and helps patients better understand and use their asthma medications.\n\nThis research may help identify a practical way to improve access to asthma specialists and reduce the burden of asthma for patients who frequently rely on emergency care.",[25,26,27,28],"Asthma Attack","Asthma Control","Asthma Exacerbations","Asthma",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"asthma","asthma exacerbation","asthma control","inhaled corticosteroid","Long-Acting Beta-Agonist","Long-Acting Muscarinic Antagonist","Emergency Room","Asthma Control Test","Medication Adherence Report Scale for Asthma","Asthma Symptom Utility Index","barriers to care","social determinants of health","access to care","telehealth","telemedicine","NOT_YET_RECRUITING","2026-05-22",{"date":48,"type":49},"2026-05-26","ACTUAL",{"date":51,"type":19},"2026-06",{"date":53,"type":19},"2027-06",{"name":55,"class":56},"Juan Carlos Cardet","OTHER",{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":15,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":20,"phases":69,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100630340","blood-eosinophil-guided-versus-usual-care-in-the-management-of-mild-to-moderate-asthma-at-primary-care-beam-100630340","NCT07486401","Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)","Randomised Controlled Trial Of Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)","BEAM","Inclusion Criteria:\n\n1. Singaporeans or Singapore Permanent Residents\n2. Patients aged ≥21 to 65 years old\n3. Physician diagnosed asthma for duration of at least 4 weeks\n4. On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment\n5. No asthma exacerbations\\* in the preceding 4 weeks before randomisation\n6. Able and willing to attend study appointments approximately every 4-monthly over a 1-year period\n7. Able to provide informed consent\n8. Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) \\*Exacerbations are defined as worsening of asthma symptoms requiring systemic corticosteroid for 3 or more days, emergency department visit, or hospitalization\n\nExclusion Criteria:\n\n1. History of life-threatening asthma requiring intubation or intensive care unit admission\n2. Severe asthma or difficult to treat asthma\n3. Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids\n4. Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion\n5. Current use of beta-blocking agents including eye-drops\n6. Use of oral, rectal, or parenteral glucocorticoid within 30 days and\u002For depot parenteral glucocorticoid within 12 weeks prior to recruitment\n7. Known diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease or bronchiectasis\n8. Any significant disease or disorder (eg. Cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study\n9. Current enrolment in other interventional clinical trial for asthma\n10. Female subjects who are pregnant or planning pregnancy during the study period\n11. Planned travel outside of the country for ≥16 consecutive weeks during the study\n12. Investigator's assessment of poor capability of following study instructions or comply with study procedures","21 Years","65 Years",{"count":68,"type":19},240,[22],"The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting.\n\nThe study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting.\n\nResearchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management",[27,72,73],"Biomarkers \u002F Blood","Eosinophil Blood Count",[28,75,76,77,78],"Mild-moderate Asthma","Blood Biomarkers","Eosinophil","Primary Care","RECRUITING","2026-03-18",{"date":82,"type":49},"2026-03-20",{"date":84,"type":49},"2025-12-03",{"date":86,"type":19},"2029-12-31",{"name":88,"class":89},"National Healthcare Group Polyclinics","OTHER_GOV",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":20,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100615453","bronchial-thermoplasty-for-adults-with-severe-asthma-in-the-biologic-era-100615453","NCT07292805","Bronchial Thermoplasty for Adults With Severe Asthma in the Biologic Era","Bronchial Thermoplasty (BT) for Severe Asthma in the Biologic Era: a Randomized Controlled Trial (BOOSTER Trial)","BOOSTER","Inclusion Criteria:\n\n* adult (\\>18 years)\n* severe uncontrolled asthma (defined as ACQ above 1.5) despite optimal medical therapy (GINA treatment step 5; alternative diseases excluded, therapy compliance and adequate inhalation technique confirmed)\n* 1 or more trials of treatment with a biologic or ineligible for biologic treatment\n* 2 or more severe asthma exacerbations in the previous year (defined as the need for a course of OCS or doubling dose of maintenance OCS for at least 3 consecutive days)\n* FEV1 ≥ 50% predicted after 400μg inhaled salbutamol or equivalent\n\nExclusion Criteria:\n\n* chronic OCS therapy at a dose \\>20 mg\u002Fday prednisone equivalent\n* 1 or more ICU admission for mechanical or endotracheal intubation for\n* asthma in the previous year.\n* anti-coagulation therapy that cannot be stopped temporarily\n* pregnancy\n* body mass index ≥35\n* current or ex-smokers with \\>20 pack years\n* DLCOc \\\u003C70%\n* Subject has a known sensitivity to medications required to perform bronchoscopy\n* Subject is using immunosuppressant therapy other than oral steroid therapy that impact on BT\n* Subject has bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmm2 or known coagulopathy\n* Comorbidities that are a contra-indication for BT such as severe heart failure and other respiratory diseases including bronchiectasis, interstitial lung disease, emphy-sema, cystic fibrosis, mechanical upper airway obstruction, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis (ABPA)\n* Subject uses an internal or external pacemaker or cardiac defibrillator..",{"count":100,"type":19},90,[22],"Rationale: For patients with severe asthma that remain uncontrolled with exacerbations despite biologics or patients who are not eligible for biologics, there is no reimbursed treatment other than pulmonary rehabilitation in the Netherlands. Pulmonary rehabilitation is known to have a limited effect for a limited amount of time. Bronchial thermoplasty or bronchial ablation (BT) is a non-pharmacological treatment for asthma aiming to restore abnormal airway function by using an endobronchial approach. Previous RCT's reported efficacy on exacerbations and asthma related quality of life (AQLQ), but were performed before large availability of biologic treatments. Although a single BT treatment is not without costs, these costs seem to outweigh the costs that can be saved by the long-term (\\>5 years) lowering effect of BT on the frequency of exacerbations and hospitalizations and omitting long term use of trials and switches of biologics. Therefore, the investigators hypothesize that BT, in the era of biologics, is superior (in terms of exacerbations and quality of life) over standard care and cost-effective in patients whose asthma remains uncontrolled despite optimal anti-inflammatory treatments including biologics, and the investigators propose to test this hypothesis in a RCT.\n\nObjective: To investigate the impact of BT as compared to standard of care in severe asthma patients that remain uncontrolled despite standard treatment including adequate doses of inhaled preventer therapies with or without biologics on:\n\n1. rate of exacerbations\n2. asthma related quality of life (AQLQ)\n3. 1-year and 5-year cost-effectiveness and cost utility Study design: Investigator-initiated randomized, multicenter, parallel-group interventional RCT of severe asthma patients undergoing either BT (active arm) or standard care (control arm).\n\nStudy population: Adult, uncontrolled severe asthma patients despite optimal medical therapy including one or more trials of treatment with a biologic or ineligible for biologic treatment AND 2 or more severe asthma exacerbations in the previous year AND FEV1 ≥ 50% predicted.\n\nIntervention: BT (active arm) versus standard care (control arm). Main study parameters\u002Fendpoints: The primary endpoint of this study is the between group difference in severe exacerbation rate after 12 months of follow-up. The main secondary endpoints are between group differences after 12 months of follow-up and within group differences before and after intervention or standard care. Parameters that will be explored are: AQLQ (minimal clinically important difference \\>0.5), ACQ (minimal clinically important difference \\>0.5), exacerbation rate (before and after BT) and hospitalizations (rate and % subjects).",[27,104,105],"Severe Asthma","Bronchial Thermoplasty",[107,30,108,109],"bronchial thermoplasty","severe asthma","asthma exacerbations","2025-12-17",{"date":112,"type":49},"2025-12-18",{"date":114,"type":49},"2024-04-09",{"date":116,"type":19},"2029-04-30",{"name":118,"class":56},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":20,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100597012","phase-4-individualizing-treatment-for-asthma-in-primary-care-full-study-100597012","NCT07052942","Individualizing Treatment for Asthma in Primary Care (Full Study)","iTREAT-PC","Inclusion Criteria:\n\n1. A clinical asthma diagnosis for at least 1 year;\n2. 13-75 years of age;\n3. A prescription for an ICS either used regularly, or on an as needed controller, not reliever, schedule - ICS or ICS + LABA or ICS+LABA+LAMA;\n4. A current ACT total score of \\\u003C20 OR an exacerbation requiring 72 hours or more of systemic steroids or a hospitalization of at least 24 hours \\> 30 days and \\\u003C 365 days prior to enrollment;\n5. Able to provide consent (adolescents: assent) in English or Spanish; (i.e., cognitively impaired individuals are deemed not to be able to provide consent and thus do not meet inclusion criteria.);\n6. Patients with a coexisting clinical diagnosis of COPD are eligible if they meet any one of the following criteria:\n\n   (i) Never smoker without secondary lung disease causing airway obstruction. (ii) Current or former smoker with obstruction on PFTs, but normal diffusing capacity of the lungs for carbon monoxide (DLCO) in the past 24 months.\n7. Patients on medications that may interact with azithromycin but are not totally excluded may be enrolled if they agree to a cardiac rhythm strip after consent and prior to randomization (or have an ECG within the prior 24 months as a baseline assessment) and a repeat rhythm strip after one week if randomized to one of the azithromycin arms of the study.\n\nExclusion Criteria:\n\n1. Another family member living in the same household already enrolled in study;\n2. Life expectancy \\\u003C1 year (operationalized by the question to the patient's asthma care clinician \"Would you be surprised if this person died in the next 12 months? If yes - include, if no - exclude);\n3. No ICS prescribed for the individual (does not have to be using the ICS inhaler);\n4. Active treatment for hematological or solid organ cancer other than basal cell or skin squamous cell cancer (if participant is \\> 12 months out from original therapy and may be on a cancer maintenance drug that is not otherwise contraindicated they are eligible for the study);\n5. Allergy to macrolides or conditions for which macrolide administration may possibly be hazardous (e.g., acute or chronic hepatitis, cirrhosis, or other liver disease; end-stage renal disease; uncorrected hypokalemia or hypomagnesemia; clinically significant bradycardia; or history of prolonged cardiac repolarization and QT interval or evidence of prolonged cardiac repolarization on rhythm strip and QT interval or torsades de pointes);\n6. On daily or every other day oral steroids for any reason;\n7. A course of systemic steroids for an asthma exacerbation or an overnight hospitalization for an asthma exacerbation in the past month (can wait and re-check eligibility after one month);\n8. Currently on R-ICS or any antibiotic therapy expected to last more than 30 days. If on antibiotics less than 30 days, individual can enroll after they have stopped their current antibiotic for 72 hours. Individuals on biologics can be enrolled if they have been on a stable dose for \\> 6 months and meet the ACT or exacerbation criteria as well as all other criteria after being on the stable does of the biologic.\n9. On a medication with known risk (i.e., that is associated with prolonged QT and associated with torsades de pointes even when taken as recommended)- absolute contraindication to eligibility- Full lists in Appendix B;\n10. Specified medications for which close monitoring has been recommended in the setting of macrolide administration (digoxin, warfarin, theophylline, ergotamine or dihydroergotamine, cyclosporine, hexobarbital, phenytoin or nelfinavir).","13 Years","75 Years",{"count":130,"type":19},3200,[132],"PHASE4","While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects.\n\nThis study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced \"Ricks,\" and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.",[28,25,27],[136],"Intervention\u002FTreatment","2025-10-28",{"date":139,"type":49},"2025-10-29",{"date":141,"type":49},"2025-08-01",{"date":143,"type":19},"2029-11-15",{"name":145,"class":89},"DARTNet Institute",13,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":20,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100601589","phase-2-nebulized-ketamine-plus-standard-care-vs-standard-care-alone-in-moderate-to-severe-asthma-exacerbations-100601589","NCT07112456","Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations","Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations: A Randomized Clinical Trial (KET-AIR Trial)","KET-AIR","Inclusion Criteria:\n\n1. Adults aged 18 years or older presenting to the Emergency Department with a clinical diagnosis of moderate to severe asthma exacerbation based on SIGN (Scottish Intercollegiate Guidelines Network) criteria.\n2. PEFR between 33% and 75% of predicted value or personal best, as measured using a peak flow meter.\n3. Stable vital signs as deemed by the treating physician\n4. Alert and oriented, able to understand the study purpose and provide informed consent.\n5. Not requiring immediate advanced airway intervention, including intubation or emergency non-invasive ventilation.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or allergy to ketamine or any component of the nebulized solution.\n2. History of psychosis, schizophrenia, or other severe uncontrolled psychiatric disorders.\n3. Uncontrolled hypertension, defined as systolic BP \\> 180 mmHg or diastolic BP \\> 110 mmHg on two consecutive readings at least 5 minutes apart, despite initial ED management.\n4. Hemodynamic instability, including persistent hypotension (SBP \\\u003C 90 mmHg) or tachyarrhythmias requiring urgent treatment.\n5. Significant chronic lung disease, including:\n\n   * COPD with frequent exacerbations or baseline FEV₁ \\\u003C 50% predicted\n   * Interstitial lung disease (ILD)\n   * Clinically significant bronchiectasis with baseline productive cough or infection\n6. Pregnancy or currently breastfeeding.\n7. Home BiPAP use or requirement for non-invasive ventilation (e.g., BiPAP\u002FCPAP) during the ED visit (Note: isolated home CPAP for sleep apnea without daytime symptoms is acceptable).\n8. Current intubation or imminent need for mechanical ventilation based on clinical judgment.\n9. Severe cardiac disease, including decompensated heart failure, recent myocardial infarction (\\\u003C6 weeks), or known severe valvular disease.\n10. Any other medical, surgical, or psychiatric condition that in the opinion of the investigator would place the patient at undue risk from study participation or interfere with the interpretation of study results.",{"count":156,"type":19},100,[158],"PHASE2","The goal of this clinical trial is to learn if nebulized ketamine helps treat moderate to severe asthma attacks in adults in the emergency department. It will also learn about the safety of ketamine when inhaled through a nebulizer.\n\nThe main questions it aims to answer are:\n\n* Does nebulized ketamine improve breathing more than standard treatment alone?\n* What side effects, if any, do participants experience after receiving nebulized ketamine?\n\nResearchers will compare nebulized ketamine to a placebo (a saltwater mist with no medication) to see how well it works and how safe it is.\n\nParticipants will:\n\n* Receive either nebulized ketamine or a placebo mist, along with standard asthma treatment\n* Have their breathing checked before and after treatment using a peak flow meter\n* Be monitored for 60 minutes and have their symptoms, vital signs, and any side effects recorded",[161,25,27],"Asthma Acute",[28,163,164,165,166,167,168,169,170,171],"Asthma, Severe","Asthma Exacerbation","Emergency Treatment","Ketamine","Ketamine, Nebulized","Bronchodilator Agents","Randomized Controlled Trial","Peak Expiratory Flow Rate","Safety and Efficacy",{"date":173,"type":49},"2025-08-08",{"date":175,"type":19},"2026-09-01",{"date":177,"type":19},"2029-08-31",{"name":179,"class":89},"Oman Medical Speciality Board",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":20,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100580170","phase-4-dose-trial-optimal-dose-of-oral-corticosteroids-to-treat-asthma-exacerbations-100580170","NCT06833814","DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations","DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations: A Parallel, Randomized Controlled Pilot Study","DOSE","Inclusion Criteria:\n\n* Male and female volunteers\n* 18 years of age or older\n* Assessed for a severe asthma exacerbation\n* Being prescribed OCS for the management of their exacerbation\n* Able to comprehend and follow all required study procedures\n* Able to understand and give written informed consent and have signed a written informed consent form (ICF) approved by the REB\n\nExclusion Criteria:\n\n* For females, are pregnant, or lactating\n* Respiratory comorbidities other than asthma, including bronchiectasis (non-CF) or asthma-COPD overlap (ACO)\n* FEV1 \\\u003C40% of personal best or \\\u003C1 Li\n* OCS-dependent\n* Asthma exacerbation in the 4 weeks preceding the study visit\n* Concomitant disease, health condition, and\u002For lifestyle activities that could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease. These include, but are not restricted to: heart failure, previous bipolar decompensation with prednisone, severe blood hypertension, uncontrolled diabetes, pneumonia.\n* Unwilling or unable to comply with the study protocol for any other reason",{"count":189,"type":19},36,[132],"Patients with severe asthma frequently experience exacerbations of their disease. The heterogeneity of asthma exacerbations represents a major challenge for patients and healthcare providers, making treatment difficult. Current guidelines recommend varying doses of short-term oral corticosteroids (OCS) as first-line treatment for asthma exacerbations. However, studies supporting the optimal dose of OCS to treat asthma exacerbations are rare.\n\nThis study aims to evaluate the feasibility, acceptability, and safety of a randomized clinical trial with different OCS regimens for patients and physicians. Additionally, evaluate the success rate of different OCS dosages to support power calculations for a non-inferiority trial.\n\nIn this pilot, parallel, randomized, controlled study, patients with severe asthma exacerbation, considered to require treatment with OCS according to physician judgment after a complete evaluation will be randomized to 1) 3 days of 50 mg prednisone followed by 7 days of placebo, 2) 3 days of 50 mg prednisone and 4 days of 25 mg prednisone followed by 3 days of placebo, or 3) 5 days of 50 mg prednisone and 5 days of 25 mg prednisone. Randomized patients will be assessed for daily symptoms and overall perception of well-being, in addition to asthma control, quality of life as well as additional medical visits. Lung function and inflammation will also be measured. Feasibility and acceptability will be defined by a participation rate \\>80%, while safety will be defined as an increase in OCS doses in \\\u003C20% of patients in one arm or an emergency room visit in \\\u003C10% of patients in one arm. Success will be defined as no increased or prolonged doses of OCS, no re-consultation for OCS or escalation to antibiotics, reduction of symptoms, and return of lung function to \\>80% of its optimal level.\n\nIn addition to determining the feasibility and safety of different OCS regimens to treat asthma exacerbations, this trial will help us determine the optimal design for a randomized clinical trial using different OCS regimens. The exacerbation clinic is already operational with 4 to 5 patients\u002Fweek assessed and treated. We have all the resources on site to carry out this project.",[27],[31,194,195],"prednisone","randomized controlled trial","2025-02-13",{"date":198,"type":49},"2025-02-19",{"date":200,"type":19},"2025-02-17",{"date":202,"type":19},"2025-12-31",{"name":204,"class":56},"Andréanne Côté",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":15,"minAge":212,"maxAge":16,"enrollmentInfo":213,"targetDuration":4,"studyType":20,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100573751","study-on-effect-of-papworth-technique-in-anemic-asthmatic-pediatrics-100573751","NCT06750354","Study on Effect of Papworth Technique in Anemic Asthmatic Pediatrics","A Randomized Controlled Study to Evaluate the Effect of Papworth Technique and Aerobic Training on Hemoglobin and Exercise Tolerance in Anemic Asthmatic Pediatrics","Inclusion Criteria:\n\nPatients will be included:\n\n1. 40 patients from both genders.\n2. Participants between the age 12 and 18 years\n3. Oriented, medically stable and taking their medical treatment\n4. Mild and moderate asthma\n5. All patients are diagnosed as iron deficiency anemia\n6. Body mass index between 18.5 -24.9\n\nExclusion Criteria:\n\n1\\. Have any serious chest diseases, Patients with heart diseases. 2. Patients with neurological disease affecting respiratory muscles or any muscular dystrophy 3. Patients with kidney diseases 4. Patients with liver diseases 5. Other types of anaemia Chest deformities\n\n\\-","12 Years",{"count":18,"type":19},[22],"As asthma is chronic condition which interferes with quality of life and exercise tolerance, so it is important to find out cost-effective alternative for the management of asthma due to increased prevalence and rising health care cost as well . Therefore, to provide comprehensive asthma treatment, it is necessary to rule out and address the factor affecting quality of life and exercise tolerance. Asthmatics require stepwise approach which contains assessment treatment planning and review of response. Along with this modification of risk factors, controller therapy is adjusted accordingly. But this is inadequate for asthma management as pharmacological management has some side effects. So, in addition to medical care, Papworth method provides good adjuvant to control asthma symptoms. Asthma subjects require comprehensive approach to deal with these hyperinflation and hyperventilation which are common manifestations of asthma",[217,27],"Anaemia",[219,220,221],"papworth technique","aerobic training","anaemic asthmatic pediatrics","2024-12-24",{"date":224,"type":49},"2024-12-27",{"date":226,"type":19},"2024-12-20",{"date":228,"type":19},"2025-03-15",{"name":230,"class":56},"Cairo University",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":237,"sex":15,"minAge":16,"maxAge":238,"enrollmentInfo":239,"targetDuration":241,"studyType":242,"phases":4,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":90},"100563814","a-cohort-study-of-risk-factors-and-prognosis-for-frequent-acute-asthma-exacerbations-phenotype-100563814","NCT06621056","A Cohort Study of Risk Factors and Prognosis for Frequent Acute Asthma Exacerbations Phenotype","Inclusion Criteria:\n\n* Patients with asthma attending the outpatient clinic of the Department of Respiratory and Critical Care Medicine of Peking University Third Hospital met the diagnostic criteria for asthma proposed by the guidelines for the prevention and treatment of bronchial asthma.\n\nExclusion Criteria:\n\n* Combination of chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypoventilation syndrome, malignancy; combination of various acute and chronic respiratory failure; combination of severe cardiovascular disease; pregnant women.",true,"80 Years",{"count":240,"type":19},300,"1 Year","OBSERVATIONAL","Acute asthma exacerbations are an important public health problem and a major cause of disease progression and healthcare burden for people with asthma. Frequent acute exacerbations are likely to be a distinct asthma phenotype. Further research is needed to identify risk factors for frequent acute exacerbations, but previous studies have mostly been cross-sectional studies at a single time point or prospective studies based on smaller sample sizes. Moreover, most of the studies on frequent acute exacerbations have been conducted in severe or refractory asthma, whereas a certain proportion of non-severe asthmatics may also experience frequent acute exacerbations, the risk factors of which remain to be further evaluated. The main objectives of this project are to compare the baseline clinical, inflammatory, pathophysiological, comorbidities, environmental pollutants and meteorological exposure characteristics of patients with frequent acute exacerbations and those with non-frequent acute exacerbations irrespective of asthma severity, and to develop a disease prediction model for frequent acute exacerbations; and to develop a cohort of patients with frequent acute exacerbations of asthma, observe their prognosis and response to treatment, and search for prognostic factors associated with them. The successful implementation of this study will help in the early identification of patients with frequent acute exacerbations, clarify the factors associated with poor prognosis in this group of patients, and thus provide an individualized plan for the treatment and prevention of this type of patients, which is of great significance in achieving good asthma control, reducing the burden of disease, decreasing the cost of healthcare, and saving clinical healthcare resources and costs.",[27],[30],"2024-09-27",{"date":248,"type":49},"2024-10-01",{"date":250,"type":49},"2022-01-01",{"date":202,"type":19},{"name":253,"class":56},"Peking University Third Hospital"]